<!DOCTYPE html>
<html lang="en" dir="ltr">
    <head>
        <meta charset="utf-8">
        <link rel="stylesheet" href="/static/rendered_html/uslm.css">
        <link rel="stylesheet" href="/static/rendered_html/style.css">
        <script src="https://kit.fontawesome.com/2ce1080035.js" crossorigin="anonymous"></script>
        <script lang="text/javascript" src="/static/rendered_html/omni.js" defer></script>

        <!-- Table of Contents button section sheet. Would ideally be a working breadcrumb --> 
        <img src="../omni.jpg" alt="Omnibuster" style="width:100%">
        <ul class="breadcrumb" style="text-align:center">
            <!-- TODO GENERALIZE THIS --> 
            <li><a href="index.html"> Table of Contents</a></li>
            
                <li> Division A </a></li>
            
                <li> Title III </a></li>
            
                <li> Subtitle F </a></li>
            
                <li> Part II </a></li>
            
                <li> Section 3862 </a></li>
            
        </ul>


        <!-- <title> Omnibuster </title>
 -->
    </head>

    <body>
        <br><br><br>
        <div class="section">
            <div class="buttons">
                <div class="navbar">
                    <div>
                        <button onclick="highlightSelection();">Highlight Text</button>
                    </div>
                    <div>
                        <button onclick="annotateSelection();">[Not working] Annotate Text</button>
                    </div> 
                </div>
            </div>
            <p> 
                <section id="d3355e28547" identifier="/us/bill/116/hr/748/dA/tIII/stF/ptII/s3862" style="-uslm-lc:I650144"><num value="3862">SEC. 3862. </num><heading>FEES RELATING TO OVER-THE-COUNTER DRUGS.</heading><content class="indent0 fontsize10" style="-uslm-lc:I650120">  Subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (<a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section379f&amp;num=0&amp;edition=prelim"><ref href="/us/usc/t21/s379f/etseq">21 U.S.C. 379f et seq.</ref></a>) <amendingAction type="amend">is amended</amendingAction> by <amendingAction type="insert">inserting</amendingAction> after part 9 the following:<quotedContent><part style="-uslm-lc:I650173"><num value="10">“PART 10—</num><heading>FEES RELATING TO OVER-THE-COUNTER DRUGS</heading><section style="-uslm-lc:I650144"><num class="bold " value="744L">“SEC. 744L. </num><heading class="bold ">DEFINITIONS.</heading><chapeau class="indent0 fontsize10" style="-uslm-lc:I650120">  “In this part:</chapeau><paragraph class="indent1 fontsize10" role="definitions" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="1">“(1) </num><chapeau>The term ‘<term>affiliate</term>’ means a business entity that has a relationship with a second business entity if, directly or indirectly—</chapeau><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><content>one business entity controls, or has the power to control, the other business entity; or</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><content>a third party controls, or has power to control, both of the business entities.</content>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" role="definitions" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="2">“(2) </num><content>The term ‘<term>contract manufacturing organization facility</term>’ means an OTC monograph drug facility where neither the owner of such manufacturing facility nor any affiliate of such owner or facility sells the OTC monograph drug produced at such facility directly to wholesalers, retailers, or consumers in the United States.</content>
</paragraph>
<paragraph class="indent1 fontsize10" role="definitions" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="3">“(3) </num><chapeau>The term ‘<term>costs of resources allocated for OTC monograph drug activities</term>’ means the expenses in connection with OTC monograph drug activities for—</chapeau><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><content>officers and employees of the Food and Drug Administration, contractors of the Food and Drug Administration, advisory committees, and costs related to such officers, employees, and committees and costs related to contracts with such contractors;</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><content>management of information, and the acquisition, maintenance, and repair of computer resources;</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="C">“(C) </num><content>leasing, maintenance, renovation, and repair of facilities and acquisition, maintenance, and repair of fixtures, furniture, scientific equipment, and other necessary materials and supplies; and</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="D">“(D) </num><content>collecting fees under section 744M and accounting for resources allocated for OTC monograph drug activities.</content>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" role="definitions" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="4">“(4) </num><content>The term ‘<term>FDA establishment identifier</term>’ is the unique number automatically generated by Food and Drug Administration’s Field Accomplishments and Compliance Tracking System (FACTS) (or any successor system).</content>
</paragraph>
<paragraph class="indent1 fontsize10" role="definitions" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="5">“(5) </num><content>The term ‘<term>OTC monograph drug</term>’ means a nonprescription drug without an approved new drug application which is governed by the provisions of section 505G.</content>
</paragraph>
<paragraph class="indent1 fontsize10" role="definitions" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="6">“(6) </num><chapeau>The term ‘<term>OTC monograph drug activities</term>’ means activities of the Secretary associated with OTC monograph drugs and inspection of facilities associated with such products, including the following activities:</chapeau><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><chapeau>The activities necessary for review and evaluation of OTC monographs and OTC monograph order requests, including—</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>orders proposing or finalizing applicable conditions of use for OTC monograph drugs;</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>orders affecting status regarding general recognition of safety and effectiveness of an OTC monograph ingredient or combination of ingredients under specified conditions of use;</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="iii">“(iii) </num><content>all OTC monograph drug development and review activities, including intra-agency collaboration;</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="iv">“(iv) </num><content>regulation and policy development activities related to OTC monograph drugs;</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="v">“(v) </num><content>development of product standards for products subject to review and evaluation;</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="vi">“(vi) </num><content>meetings referred to in section 505G(i);</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="vii">“(vii) </num><content>review of labeling prior to issuance of orders related to OTC monograph drugs or conditions of use; and</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="viii">“(viii) </num><content>regulatory science activities related to OTC monograph drugs.</content>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><content>Inspections related to OTC monograph drugs.</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="C">“(C) </num><content>Monitoring of clinical and other research conducted in connection with OTC monograph drugs.</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="D">“(D) </num><chapeau>Safety activities with respect to OTC monograph drugs, including—</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>collecting, developing, and reviewing safety information on OTC monograph drugs, including adverse event reports;</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>developing and using improved adverse event data-collection systems, including information technology systems; and</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="iii">“(iii) </num><content>developing and using improved analytical tools to assess potential safety risks, including access to external databases.</content>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="E">“(E) </num><content>Other activities necessary for implementation of section 505G.</content>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" role="definitions" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="7">“(7) </num><content>The term ‘<term>OTC monograph order request</term>’ means a request for an order submitted under section 505G(b)(5).</content>
</paragraph>
<paragraph class="indent1 fontsize10" role="definitions" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="8">“(8) </num><content>The term ‘<term>Tier 1 OTC monograph order request</term>’ means any OTC monograph order request not determined to be a Tier 2 OTC monograph order request.</content>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="9">“(9)</num><subparagraph class="inline" role="definitions"><num value="A">(A) </num><chapeau>The term ‘<term>Tier 2 OTC monograph order request</term>’ means, subject to subparagraph (B), an OTC monograph order request for—</chapeau><clause class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>the reordering of existing information in the drug facts label of an OTC monograph drug;</content>
</clause>
<clause class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>the addition of information to the other information section of the drug facts label of an OTC monograph drug, as limited by <a href="https://www.law.cornell.edu/cfr/text/21/201.66"><ref href="/us/cfr/t21/s201.66/c/7">section 201.66(c)(7) of title 21, Code of Federal Regulations</ref></a> (or any successor regulations);</content>
</clause>
<clause class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="iii">“(iii) </num><content>modification to the directions for use section of the drug facts label of an OTC monograph drug, if such changes conform to changes made pursuant to section 505G(c)(3)(A);</content>
</clause>
<clause class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="iv">“(iv) </num><content>the standardization of the concentration or dose of a specific finalized ingredient within a particular finalized monograph;</content>
</clause>
<clause class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="v">“(v) </num><content>a change to ingredient nomenclature to align with nomenclature of a standards-setting organization; or</content>
</clause>
<clause class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="vi">“(vi) </num><content>addition of an interchangeable term in accordance with <a href="https://www.law.cornell.edu/cfr/text/21/330.1"><ref href="/us/cfr/t21/s330.1">section 330.1 of title 21, Code of Federal Regulations</ref></a> (or any successor regulations).</content>
</clause>
</subparagraph>
<subparagraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="B">“(B) </num><content>The Secretary may, based on program implementation experience or other factors found appropriate by the Secretary, characterize any OTC monograph order request as a Tier 2 OTC monograph order request (including recharacterizing a request from Tier 1 to Tier 2) and publish such determination in a proposed order issued pursuant to section 505G.</content>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="10">“(10)</num><subparagraph class="inline" role="definitions"><num value="A">(A) </num><chapeau>The term ‘<term>OTC monograph drug facility</term>’ means a foreign or domestic business or other entity that—</chapeau><clause class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="i">“(i) </num><chapeau>is—</chapeau><subclause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="I">“(I) </num><content>under one management, either direct or indirect; and</content>
</subclause>
<subclause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="II">“(II) </num><content>at one geographic location or address engaged in manufacturing or processing the finished dosage form of an OTC monograph drug;</content>
</subclause>
</clause>
<clause class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>includes a finished dosage form manufacturer facility in a contractual relationship with the sponsor of one or more OTC monograph drugs to manufacture or process such drugs; and</content>
</clause>
<clause class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="iii">“(iii) </num><content>does not include a business or other entity whose only manufacturing or processing activities are one or more of the following: production of clinical research supplies, testing, or placement of outer packaging on packages containing multiple products, for such purposes as creating multipacks, when each monograph drug product contained within the overpackaging is already in a final packaged form prior to placement in the outer overpackaging.</content>
</clause>
</subparagraph>
<subparagraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="B">“(B) </num><chapeau>For purposes of subparagraph (A)(i)(II), separate buildings or locations within close proximity are considered to be at one geographic location or address if the activities conducted in such buildings or locations are—</chapeau><clause class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>closely related to the same business enterprise;</content>
</clause>
<clause class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>under the supervision of the same local management; and</content>
</clause>
<clause class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="iii">“(iii) </num><content>under a single FDA establishment identifier and capable of being inspected by the Food and Drug Administration during a single inspection.</content>
</clause>
</subparagraph>
<subparagraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="C">“(C) </num><content>If a business or other entity would meet criteria specified in subparagraph (A), but for being under multiple management, the business or other entity is deemed to constitute multiple facilities, one per management entity, for purposes of this paragraph.</content>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" role="definitions" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="11">“(11) </num><content>The term ‘<term>OTC monograph drug meeting</term>’ means any meeting regarding the content of a proposed OTC monograph order request.</content>
</paragraph>
<paragraph class="indent1 fontsize10" role="definitions" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="12">“(12) </num><content>The term ‘<term>person</term>’ includes an affiliate of a person.</content>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="13">“(13) </num><content>The terms ‘requestor’ and ‘sponsor’ have the meanings given such terms in section 505G.</content>
</paragraph>
</section>
<section style="-uslm-lc:I650144"><num class="bold " value="744M">“SEC. 744M. </num><heading class="bold ">AUTHORITY TO ASSESS AND USE OTC MONOGRAPH FEES.</heading><subsection class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="a">“(a) </num><heading><inline class="small-caps">Types of Fees</inline>.—</heading><chapeau>Beginning with fiscal year 2021, the Secretary shall assess and collect fees in accordance with this section as follows:</chapeau><paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="1">“(1) </num><heading><inline class="small-caps">Facility fee</inline>.—</heading><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><heading><inline class="small-caps">In general</inline>.—</heading><content>Each person that owns a facility identified as an OTC monograph drug facility on December 31 of the fiscal year or at any time during the preceding 12-month period shall be assessed an annual fee for each such facility as determined under subsection (c).</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><heading><inline class="small-caps">Exceptions</inline>.—</heading><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><heading><inline class="small-caps">Facilities that cease activities</inline>.—</heading><chapeau>A fee shall not be assessed under subparagraph (A) if the identified OTC monograph drug facility—</chapeau><subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="I">“(I) </num><content>has ceased all activities related to OTC monograph drugs prior to December 31 of the year immediately preceding the applicable fiscal year; and</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="II">“(II) </num><content>has updated its registration to reflect such change under the requirements for drug establishment registration set forth in section 510.</content>
</subclause>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><heading><inline class="small-caps">Contract manufacturing organizations</inline>.—</heading><content>The amount of the fee for a contract manufacturing organization facility shall be equal to two-thirds of the amount of the fee for an OTC monograph drug facility that is not a contract manufacturing organization facility.</content>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="C">“(C) </num><heading><inline class="small-caps">Amount</inline>.—</heading><content>The amount of fees established under subparagraph (A) shall be established under subsection (c).</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="D">“(D) </num><heading><inline class="small-caps">Due date</inline>.—</heading><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><heading><inline class="small-caps">For first program year</inline>.—</heading><chapeau>For fiscal year 2021, the facility fees required under subparagraph (A) shall be due on the later of—</chapeau><subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="I">“(I) </num><content>the first business day of July of 2020; or</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="II">“(II) </num><content>45 calendar days after publication of the Federal Register notice provided for under subsection (c)(4)(A).</content>
</subclause>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><heading><inline class="small-caps">Subsequent fiscal years</inline>.—</heading><chapeau>For each fiscal year after fiscal year 2021, the facility fees required under subparagraph (A) shall be due on the later of—</chapeau><subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="I">“(I) </num><content>the first business day of June of such year; or</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="II">“(II) </num><content>the first business day after the enactment of an appropriations Act providing for the collection and obligation of fees under this section for such year.</content>
</subclause>
</clause>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="2">“(2) </num><heading><inline class="small-caps">OTC monograph order request fee</inline>.—</heading><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><heading><inline class="small-caps">In general</inline>.—</heading><chapeau>Each person that submits an OTC monograph order request shall be subject to a fee for an OTC monograph order request. The amount of such fee shall be—</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>for a Tier 1 OTC monograph order request, $500,000, adjusted for inflation for the fiscal year (as determined under subsection (c)(1)(B)); and</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>for a Tier 2 OTC monograph order request, $100,000, adjusted for inflation for the fiscal year (as determined under subsection (c)(1)(B)).</content>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><heading><inline class="small-caps">Due date</inline>.—</heading><content>The OTC monograph order request fees required under subparagraph (A) shall be due on the date of submission of the OTC monograph order request.</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="C">“(C) </num><heading><inline class="small-caps">Exception for certain safety changes</inline>.—</heading><chapeau>A person who is named as the requestor in an OTC monograph order shall not be subject to a fee under subparagraph (A) if the Secretary finds that the OTC monograph order request seeks to change the drug facts labeling of an OTC monograph drug in a way that would add to or strengthen—</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>a contraindication, warning, or precaution;</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>a statement about risk associated with misuse or abuse; or</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="iii">“(iii) </num><content>an instruction about dosage and administration that is intended to increase the safe use of the OTC monograph drug.</content>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="D">“(D) </num><heading><inline class="small-caps">Refund of fee if order request is recategorized as a tier 2 otc monograph order request</inline>.—</heading><content>If the Secretary determines that an OTC monograph request initially characterized as Tier 1 shall be re-characterized as a Tier 2 OTC monograph order request, and the requestor has paid a Tier 1 fee in accordance with subparagraph (A)(i), the Secretary shall refund the requestor the difference between the Tier 1 and Tier 2 fees determined under subparagraphs (A)(i) and (A)(ii), respectively.</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="E">“(E) </num><heading><inline class="small-caps">Refund of fee if order request refused for filing or withdrawn before filing</inline>.—</heading><content>The Secretary shall refund 75 percent of the fee paid under subparagraph (B) for any order request which is refused for filing or was withdrawn before being accepted or refused for filing.</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="F">“(F) </num><heading><inline class="small-caps">Fees for order requests previously refused for filing or withdrawn before filing</inline>.—</heading><content>An OTC monograph order request that was submitted but was refused for filing, or was withdrawn before being accepted or refused for filing, shall be subject to the full fee under subparagraph (A) upon being resubmitted or filed over protest.</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="G">“(G) </num><heading><inline class="small-caps">Refund of fee if order request withdrawn</inline>.—</heading><content>If an order request is withdrawn after the order request was filed, the Secretary may refund the fee or a portion of the fee if no substantial work was performed on the order request after the application was filed. The Secretary shall have the sole discretion to refund a fee or a portion of the fee under this subparagraph. A determination by the Secretary concerning a refund under this subparagraph shall not be reviewable.</content>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="3">“(3) </num><heading><inline class="small-caps">Refunds</inline>.—</heading><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><heading><inline class="small-caps">In general</inline>.—</heading><content>Other than refunds provided pursuant to any of subparagraphs (D) through (G) of paragraph (2), the Secretary shall not refund any fee paid under paragraph (1) except as provided in subparagraph (B).</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><heading><inline class="small-caps">Disputes concerning fees</inline>.—</heading><content>To qualify for the return of a fee claimed to have been paid in error under paragraph (1) or (2), a person shall submit to the Secretary a written request justifying such return within 180 calendar days after such fee was paid.</content>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="4">“(4) </num><heading><inline class="small-caps">Notice</inline>.—</heading><content>Within the timeframe specified in subsection (c), the Secretary shall publish in the Federal Register the amount of the fees under paragraph (1) for such fiscal year.</content>
</paragraph>
</subsection>
<subsection class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="b">“(b) </num><heading><inline class="small-caps">Fee Revenue Amounts</inline>.—</heading><paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="1">“(1) </num><heading><inline class="small-caps">Fiscal year 2021</inline>.—</heading><chapeau>For fiscal year 2021, fees under subsection (a)(1) shall be established to generate a total facility fee revenue amount equal to the sum of—</chapeau><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><content>the annual base revenue for fiscal year 2021 (as determined under paragraph (3));</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><content>the dollar amount equal to the operating reserve adjustment for the fiscal year, if applicable (as determined under subsection (c)(2)); and</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="C">“(C) </num><content>additional direct cost adjustments (as determined under subsection (c)(3)).</content>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="2">“(2) </num><heading><inline class="small-caps">Subsequent fiscal years</inline>.—</heading><chapeau>For each of the fiscal years 2022 through 2025, fees under subsection (a)(1) shall be established to generate a total facility fee revenue amount equal to the sum of—</chapeau><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><content>the annual base revenue for the fiscal year (as determined under paragraph (3));</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><content>the dollar amount equal to the inflation adjustment for the fiscal year (as determined under subsection (c)(1));</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="C">“(C) </num><content>the dollar amount equal to the operating reserve adjustment for the fiscal year, if applicable (as determined under subsection (c)(2));</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="D">“(D) </num><content>additional direct cost adjustments (as determined under subsection (c)(3)); and</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="E">“(E) </num><chapeau>additional dollar amounts for each fiscal year as follows:</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>$7,000,000 for fiscal year 2022.</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>$6,000,000 for fiscal year 2023.</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="iii">“(iii) </num><content>$7,000,000 for fiscal year 2024.</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="iv">“(iv) </num><content>$3,000,000 for fiscal year 2025.</content>
</clause>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="3">“(3) </num><heading><inline class="small-caps">Annual base revenue</inline>.—</heading><chapeau>For purposes of paragraphs (1)(A) and (2)(A), the dollar amount of the annual base revenue for a fiscal year shall be—</chapeau><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><content>for fiscal year 2021, $8,000,000; and</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><content>for fiscal years 2022 through 2025, the dollar amount of the total revenue amount established under this subsection for the previous fiscal year, not including any adjustments made under subsection (c)(2) or (c)(3).</content>
</subparagraph>
</paragraph>
</subsection>
<subsection class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="c">“(c) </num><heading><inline class="small-caps">Adjustments; Annual Fee Setting</inline>.—</heading><paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="1">“(1) </num><heading><inline class="small-caps">Inflation adjustment</inline>.—</heading><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><heading><inline class="small-caps">In general</inline>.—</heading><chapeau>For purposes of subsection (b)(2)(B), the dollar amount of the inflation adjustment to the annual base revenue for fiscal year 2022 and each subsequent fiscal year shall be equal to the product of—</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>such annual base revenue for the fiscal year under subsection (b)(2); and</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>the inflation adjustment percentage under subparagraph (C).</content>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><heading><inline class="small-caps">OTC monograph order request fees</inline>.—</heading><chapeau>For purposes of subsection (a)(2), the dollar amount of the inflation adjustment to the fee for OTC monograph order requests for fiscal year 2022 and each subsequent fiscal year shall be equal to the product of—</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>the applicable fee under subsection (a)(2) for the preceding fiscal year; and</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>the inflation adjustment percentage under subparagraph (C).</content>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="C">“(C) </num><heading><inline class="small-caps">Inflation adjustment percentage</inline>.—</heading><chapeau>The inflation adjustment percentage under this subparagraph for a fiscal year is equal to—</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>for each of fiscal years 2022 and 2023, the average annual percent change that occurred in the Consumer Price Index for urban consumers (Washington-Baltimore, DC–MD–VA–WV; Not Seasonally Adjusted; All items; Annual Index) for the first 3 years of the preceding 4 years of available data; and</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><chapeau>for each of fiscal years 2024 and 2025, the sum of—</chapeau><subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="I">“(I) </num><content>the average annual percent change in the cost, per full-time equivalent position of the Food and Drug Administration, of all personnel compensation and benefits paid with respect to such positions for the first 3 years of the preceding 4 fiscal years, multiplied by the proportion of personnel compensation and benefits costs to total costs of OTC monograph drug activities for the first 3 years of the preceding 4 fiscal years; and</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="II">“(II) </num><content>the average annual percent change that occurred in the Consumer Price Index for urban consumers (Washington-Baltimore, DC–MD–VA–WV; Not Seasonally Adjusted; All items; Annual Index) for the first 3 years of the preceding 4 years of available data multiplied by the proportion of all costs other than personnel compensation and benefits costs to total costs of OTC monograph drug activities for the first 3 years of the preceding 4 fiscal years.</content>
</subclause>
</clause>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="2">“(2) </num><heading><inline class="small-caps">Operating reserve adjustment</inline>.—</heading><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><heading><inline class="small-caps">In general</inline>.—</heading><content>For fiscal year 2021 and subsequent fiscal years, for purposes of subsections (b)(1)(B) and (b)(2)(C), the Secretary may, in addition to adjustments under paragraph (1), further increase the fee revenue and fees if such an adjustment is necessary to provide operating reserves of carryover user fees for OTC monograph drug activities for not more than the number of weeks specified in subparagraph (B).</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><heading><inline class="small-caps">Number of weeks</inline>.—</heading><chapeau>The number of weeks specified in this subparagraph is—</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>3 weeks for fiscal year 2021;</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>7 weeks for fiscal year 2022;</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="iii">“(iii) </num><content>10 weeks for fiscal year 2023;</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="iv">“(iv) </num><content>10 weeks for fiscal year 2024; and</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="v">“(v) </num><content>10 weeks for fiscal year 2025.</content>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="C">“(C) </num><heading><inline class="small-caps">Decrease</inline>.—</heading><content>If the Secretary has carryover balances for such process in excess of 10 weeks of the operating reserves referred to in subparagraph (A), the Secretary shall decrease the fee revenue and fees referred to in such subparagraph to provide for not more than 10 weeks of such operating reserves.</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="D">“(D) </num><heading><inline class="small-caps">Rationale for adjustment</inline>.—</heading><content>If an adjustment under this paragraph is made, the rationale for the amount of the increase or decrease (as applicable) in fee revenue and fees shall be contained in the annual Federal Register notice under paragraph (4) establishing fee revenue and fees for the fiscal year involved.</content>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="3">“(3) </num><heading><inline class="small-caps">Additional direct cost adjustment</inline>.—</heading><chapeau>The Secretary shall, in addition to adjustments under paragraphs (1) and (2), further increase the fee revenue and fees for purposes of subsection (b)(2)(D) by an amount equal to—</chapeau><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><content>$14,000,000 for fiscal year 2021;</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><content>$7,000,000 for fiscal year 2022;</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="C">“(C) </num><content>$4,000,000 for fiscal year 2023;</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="D">“(D) </num><content>$3,000,000 for fiscal year 2024; and</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="E">“(E) </num><content>$3,000,000 for fiscal year 2025.</content>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="4">“(4) </num><heading><inline class="small-caps">Annual fee setting</inline>.—</heading><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><heading><inline class="small-caps">Fiscal year 2021</inline>.—</heading><chapeau>The Secretary shall, not later than the second Monday in May of 2020—</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>establish OTC monograph drug facility fees for fiscal year 2021 under subsection (a), based on the revenue amount for such year under subsection (b) and the adjustments provided under this subsection; and</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>publish fee revenue, facility fees, and OTC monograph order requests in the Federal Register.</content>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><heading><inline class="small-caps">Subsequent fiscal years</inline>.—</heading><chapeau>The Secretary shall, for each fiscal year that begins after September 30, 2021, not later than the second Monday in March that precedes such fiscal year—</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><chapeau>establish for such fiscal year, based on the revenue amounts under subsection (b) and the adjustments provided under this subsection—</chapeau><subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="I">“(I) </num><content>OTC monograph drug facility fees under subsection (a)(1); and</content>
</subclause>
<subclause class="indent4 fontsize10" style="-uslm-lc:I650128"><num style="-uslm-lc:emspace2" value="II">“(II) </num><content>OTC monograph order request fees under subsection (a)(2); and</content>
</subclause>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>publish such fee revenue amounts, facility fees, and OTC monograph order request fees in the Federal Register.</content>
</clause>
</subparagraph>
</paragraph>
</subsection>
<subsection class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="d">“(d) </num><heading><inline class="small-caps">Identification of Facilities</inline>.—</heading><chapeau>Each person that owns an OTC monograph drug facility shall submit to the Secretary the information required under this subsection each year. Such information shall, for each fiscal year—</chapeau><paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="1">“(1) </num><content>be submitted as part of the requirements for drug establishment registration set forth in section 510; and</content>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="2">“(2) </num><content>include for each such facility, at a minimum, identification of the facility’s business operation as that of an OTC monograph drug facility.</content>
</paragraph>
</subsection>
<subsection class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="e">“(e) </num><heading><inline class="small-caps">Effect of Failure To Pay Fees</inline>.—</heading><paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="1">“(1) </num><heading><inline class="small-caps">OTC monograph drug facility fee</inline>.—</heading><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><heading><inline class="small-caps">In general</inline>.—</heading><chapeau>Failure to pay the fee under subsection (a)(1) within 20 calendar days of the due date as specified in subparagraph (D) of such subsection shall result in the following:</chapeau><clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="i">“(i) </num><content>The Secretary shall place the facility on a publicly available arrears list.</content>
</clause>
<clause class="indent3 fontsize10" style="-uslm-lc:I650126"><num style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>All OTC monograph drugs manufactured in such a facility or containing an ingredient manufactured in such a facility shall be deemed misbranded under section 502(ff).</content>
</clause>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><heading><inline class="small-caps">Application of penalties</inline>.—</heading><content>The penalties under this paragraph shall apply until the fee established by subsection (a)(1) is paid.</content>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="2">“(2) </num><heading><inline class="small-caps">Order requests</inline>.—</heading><content>An OTC monograph order request submitted by a person subject to fees under subsection (a) shall be considered incomplete and shall not be accepted for filing by the Secretary until all fees owed by such person under this section have been paid.</content>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="3">“(3) </num><heading><inline class="small-caps">Meetings</inline>.—</heading><content>A person subject to fees under this section shall be considered ineligible for OTC monograph drug meetings until all such fees owed by such person have been paid.</content>
</paragraph>
</subsection>
<subsection class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="f">“(f) </num><heading><inline class="small-caps">Crediting and Availability of Fees</inline>.—</heading><paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="1">“(1) </num><heading><inline class="small-caps">In general</inline>.—</heading><content>Fees authorized under subsection (a) shall be collected and available for obligation only to the extent and in the amount provided in advance in appropriations Acts. Such fees are authorized to remain available until expended. Such sums as may be necessary may be transferred from the Food and Drug Administration salaries and expenses appropriation account without fiscal year limitation to such appropriation account for salaries and expenses with such fiscal year limitation. The sums transferred shall be available solely for OTC monograph drug activities.</content>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="2">“(2) </num><heading><inline class="small-caps">Collections and appropriation acts</inline>.—</heading><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><heading><inline class="small-caps">In general</inline>.—</heading><content>Subject to subparagraph (C), the fees authorized by this section shall be collected and available in each fiscal year in an amount not to exceed the amount specified in appropriation Acts, or otherwise made available for obligation, for such fiscal year.</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><heading><inline class="small-caps">Use of fees and limitation</inline>.—</heading><content>The fees authorized by this section shall be available to defray increases in the costs of the resources allocated for OTC monograph drug activities (including increases in such costs for an additional number of full-time equivalent positions in the Department of Health and Human Services to be engaged in such activities), only if the Secretary allocates for such purpose an amount for such fiscal year (excluding amounts from fees collected under this section) no less than $12,000,000, multiplied by the adjustment factor applicable to the fiscal year involved under subsection (c)(1).</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="C">“(C) </num><heading><inline class="small-caps">Compliance</inline>.—</heading><content>The Secretary shall be considered to have met the requirements of subparagraph (B) in any fiscal year if the costs funded by appropriations and allocated for OTC monograph drug activities are not more than 15 percent below the level specified in such subparagraph.</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="D">“(D) </num><heading><inline class="small-caps">Provision for early payments in subsequent years</inline>.—</heading><content>Payment of fees authorized under this section for a fiscal year (after fiscal year 2021), prior to the due date for such fees, may be accepted by the Secretary in accordance with authority provided in advance in a prior year appropriations Act.</content>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="3">“(3) </num><heading><inline class="small-caps">Authorization of appropriations</inline>.—</heading><content>For each of the fiscal years 2021 through 2025, there is authorized to be appropriated for fees under this section an amount equal to the total amount of fees assessed for such fiscal year under this section.</content>
</paragraph>
</subsection>
<subsection class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="g">“(g) </num><heading><inline class="small-caps">Collection of Unpaid Fees</inline>.—</heading><content>In any case where the Secretary does not receive payment of a fee assessed under subsection (a) within 30 calendar days after it is due, such fee shall be treated as a claim of the United States Government subject to <a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title31-sectionh37&amp;num=0&amp;edition=prelim"><ref href="/us/usc/t31/ch37/schII">subchapter II of chapter 37 of title 31, United States Code</ref></a>.</content>
</subsection>
<subsection class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="h">“(h) </num><heading><inline class="small-caps">Construction</inline>.—</heading><content>This section may not be construed to require that the number of full-time equivalent positions in the Department of Health and Human Services, for officers, employers, and advisory committees not engaged in OTC monograph drug activities, be reduced to offset the number of officers, employees, and advisory committees so engaged.</content>
</subsection>
</section>
<section style="-uslm-lc:I650144"><num class="bold " value="744N">“SEC. 744N. </num><heading class="bold ">REAUTHORIZATION; REPORTING REQUIREMENTS.</heading><subsection class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="a">“(a) </num><heading><inline class="small-caps">Performance Report</inline>.—</heading><content>Beginning with fiscal year 2021, and not later than 120 calendar days after the end of each fiscal year thereafter for which fees are collected under this part, the Secretary shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report concerning the progress of the Food and Drug Administration in achieving the goals identified in the letters described in section 3861(b) of the CARES Act during such fiscal year and the future plans of the Food and Drug Administration for meeting such goals.</content>
</subsection>
<subsection class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="b">“(b) </num><heading><inline class="small-caps">Fiscal Report</inline>.—</heading><content>Not later than 120 calendar days after the end of fiscal year 2021 and each subsequent fiscal year for which fees are collected under this part, the Secretary shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report on the implementation of the authority for such fees during such fiscal year and the use, by the Food and Drug Administration, of the fees collected for such fiscal year.</content>
</subsection>
<subsection class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="c">“(c) </num><heading><inline class="small-caps">Public Availability</inline>.—</heading><content>The Secretary shall make the reports required under subsections (a) and (b) available to the public on the internet website of the Food and Drug Administration.</content>
</subsection>
<subsection class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="d">“(d) </num><heading><inline class="small-caps">Reauthorization</inline>.—</heading><paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="1">“(1) </num><heading><inline class="small-caps">Consultation</inline>.—</heading><chapeau>In developing recommendations to present to the Congress with respect to the goals described in subsection (a), and plans for meeting the goals, for OTC monograph drug activities for the first 5 fiscal years after fiscal year 2025, and for the reauthorization of this part for such fiscal years, the Secretary shall consult with—</chapeau><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><content>the Committee on Energy and Commerce of the House of Representatives;</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><content>the Committee on Health, Education, Labor, and Pensions of the Senate;</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="C">“(C) </num><content>scientific and academic experts;</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="D">“(D) </num><content>health care professionals;</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="E">“(E) </num><content>representatives of patient and consumer advocacy groups; and</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="F">“(F) </num><content>the regulated industry.</content>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="2">“(2) </num><heading><inline class="small-caps">Public review of recommendations</inline>.—</heading><chapeau>After negotiations with the regulated industry, the Secretary shall—</chapeau><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><content>present the recommendations developed under paragraph (1) to the congressional committees specified in such paragraph;</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><content>publish such recommendations in the Federal Register;</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="C">“(C) </num><content>provide for a period of 30 calendar days for the public to provide written comments on such recommendations;</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="D">“(D) </num><content>hold a meeting at which the public may present its views on such recommendations; and</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="E">“(E) </num><content>after consideration of such public views and comments, revise such recommendations as necessary.</content>
</subparagraph>
</paragraph>
<paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="3">“(3) </num><heading><inline class="small-caps">Transmittal of recommendations</inline>.—</heading><content>Not later than January 15, 2025, the Secretary shall transmit to the Congress the revised recommendations under paragraph (2), a summary of the views and comments received under such paragraph, and any changes made to the recommendations in response to such views and comments.”</content>
</paragraph>
</subsection>
</section>
</part></quotedContent>.</content>
</section>
            </p>
        </div>  

        <!-- previous section -->
        <button onclick="location.href='section_s3861.html'" id="ls-btn-prev-sec" title="go to previous section">
            <i class="fas fa-angle-left"></i>
        </button>
        <!-- end previous section -->

        <!-- next section -->
        <button onclick="location.href='section_None.html'" id="ls-btn-next-sec" title="go to next section" data-ls-target-index="2">
            <i class="fas fa-angle-right"></i>
        </button>
        <!-- end next section -->

    </body>
